Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMDs) for early cancer ...

South Korean researchers have developed a new technology that can recognize and detect lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), lung fibrosis, asthma, etc., by utilizing ...

TEM teams with Median to add FDA-cleared eyonis LCS to Pixel, boosting AI lung cancer screening and expanding its imaging portfolio.

eyonis® LCS aims to redefine lung cancer screening by supporting diagnosis at early, curable stages, while reducing false positives to avoid unnecessary follow-up procedures, and has the potential to ...

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device ...

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), manufacturer of eyonis®, a suite of artificial ...

Oran Muduroglu, proven medical imaging entrepreneur, to lead U.S. launch of eyonis LCS Established U.S. commercial and clinical infrastructure combined with Medicare reimbursement pathway already in ...

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Add Yahoo as a preferred source to see more of our stories on Google. Lung cancer screening can save lives, but it isn't accessible to everyone at risk of developing the disease. sudok1/iStock via ...

Electronic nose (e-nose) technology identified early-stage lung cancer with high reliability in a prospective observational clinical trial conducted at Memorial Sloan Kettering Cancer Center (MSK).

Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even before symptoms occur.

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA/SME eligible, “Median” or “The Company”), a leading developer of eyonis™, a suite of ...